市場調查報告書
商品編碼
1434028
醫療保健市場中的生成式人工智慧 - 應用(個人化治療、患者援助、患者監測和預測分析、醫學影像分析和診斷、藥物發現和開發)、最終用途、2024 - 2032 年全球預測Generative AI in Healthcare Market - Application (Personalized Treatment, Patient Assistance, Patient Monitoring & Predictive Analytics, Medical Image Analysis & Diagnostics, Drug Discovery & Development), End-use, Global Forecast 2024 - 2032 |
在醫療保健系統現代化計畫投資不斷增加的推動下,醫療保健市場中的生成式人工智慧從 2024 年到 2032 年的CAGR預計將達到 32.6%。
醫療保健提供者和領先組織正致力於透過投資人工智慧驅動的解決方案來簡化流程,例如患者分診、醫學影像分析以及用於增強診斷和個人化治療的藥物發現,從而改善患者治療結果和營運效率。例如,2023 年 10 月,美洲開發銀行發放了 4,000 萬美元貸款,透過擴大和改善服務基礎設施和設備來增加醫療保健的可及性和有效性,以加強巴西的衛生系統。
隨著醫療保健數位轉型的全球趨勢,在改善訪問、品質和成本效益的需求的引領下,生成式人工智慧正在獲得巨大的吸引力。此外,一些產業參與者正在推出創新解決方案,以滿足不斷變化的患者需求,進一步增強產業前景。舉個例子,2023 年 12 月,Google在 MedLM 下推出了兩個新的醫療保健生成人工智慧模型,為醫療保健組織在為各種工作部署人工智慧時提供靈活性。
醫療保健產業的生成式人工智慧分為應用程式、最終用途和區域。
在應用方面,患者監測和預測分析領域的市場佔有率預計在 2024 年至 2032 年間將達到 32.1% 的CAGR。生成式人工智慧能夠即時監測患者健康資料和預測分析,從而使醫療保健提供者能夠預測和預防不良事件。人工智慧驅動的演算法透過分析大量資料集來幫助識別模式和趨勢,以促進早期疾病檢測和個人化治療策略。
對此類創新解決方案的需求是由對主動醫療保健管理、改善患者治療結果和最佳化醫療保健資源的日益重視所推動的,進一步為行業參與者提供了潛在的成長機會。舉個例子,2023 年 9 月,Oracle 推出了醫療保健生成人工智慧功能,利用語音技術增強患者互動、建立信任並改善治療。
就最終用途而言,由於擴大使用生成式人工智慧解決方案來加快藥物發現流程、最佳化臨床,製藥和生命科學公司領域的生成式人工智慧在醫療保健行業規模的CAGR預計從2024 年到2032 年將達到33%。試驗,並開發個人化療法。製藥公司正在利用人工智慧產生的見解和預測模型來提高研發效率、降低成本並加快新療法的上市時間。此外,產生人工智慧有助於破解複雜的生物資料,以促進精準醫療計劃,從而促進該細分市場的成長。
從地區來看,到2032 年,亞太地區醫療保健產業的生成式AI 成長率預計將超過32%。隨著醫療保健系統越來越擁抱科技進步,生成式AI 已成為疾病預測、藥物發現和個人化治療的變革性工具。龐大的患者群體,加上不斷成長的醫療保健支出和政府促進數位醫療保健的舉措,正在加速生成式人工智慧解決方案的區域採用。例如,2023 年 9 月,埃維諾宣佈在東南亞正式推出首個生成式 AI 實驗室,以促進該地區的產業變革並培養當地人才。
Generative AI in Healthcare Market is set to expand at 32.6% CAGR from 2024-2032 driven by the rising investments in healthcare system modernization initiatives.
Healthcare providers and leading organizations are focusing on improving patient outcomes and operational efficiency by investing in AI-driven solutions to streamline processes, such as patient triage, medical imaging analysis, and drug discovery for enhanced diagnostics and personalized treatments. For instance, in October 2023, the Inter-American Development Bank granted a $40 million loan to strengthen Brazil's health system by increasing access and effectiveness to healthcare via the expansion and improvement of service infrastructure and equipment.
With the global trend of digital transformation in healthcare, led by the need for improved access, quality, and cost-effectiveness, generative AI is gaining significant traction. Moreover, several industry players are introducing innovative solutions for catering to the evolving patient needs, further augmenting the industry outlook. To cite an instance, in December 2023, Google launched two of its new generative AI models for healthcare under MedLM, to provide flexibility to healthcare organizations as they deploy AI for various jobs.
The generative AI in healthcare industry is segmented into application, end-use, and region.
In terms of application, the market share from the patient monitoring and predictive analytics segment is projected to record 32.1% CAGR between 2024 and 2032. Generative AI enables real-time monitoring of patient health data and predictive analytics for allowing healthcare providers to anticipate and prevent adverse events. AI-powered algorithms help identify patterns and trends by analyzing vast datasets for facilitating early disease detection and personalized treatment strategies.
The demand for such innovative solutions is driven by the increasing emphasis on proactive healthcare management, improved patient outcomes, and the optimization of healthcare resources, further offering potential growth opportunities to the industry participants. To cite an instance, in September 2023, Oracle launched healthcare-generative AI capabilities to leverage speech technology to enhance patient interaction, develop trust, and improve treatment.
In terms of end-use, the generative AI in healthcare industry size from the pharmaceutical and life science companies segment is set to witness 33% CAGR from 2024-2032 attributed to the increasing use of generative AI solutions to expedite drug discovery processes, optimize clinical trials, and develop personalized therapies. Pharmaceutical firms are harnessing AI-generated insights and predictive modeling to enhance R&D efficiency, reduce costs, and accelerate time-to-market for novel treatments. Additionally, generative AI aids in deciphering complex biological data for facilitating precision medicine initiatives, contributing to the segment growth.
Regionally, the Asia Pacific generative AI in healthcare industry is slated to depict over 32% growth rate through 2032. Generative AI has emerged as a transformative tool for disease prediction, drug discovery, and personalized treatment with healthcare systems increasingly embracing technological advancements. The large patient population, coupled with the rising healthcare expenditure and government initiatives for promoting digital healthcare is accelerating the regional adoption of generative AI solutions. For instance, in September 2023, Avanade announced the official debut of its first Generative AI Lab in Southeast Asia for enabling industrial change and developing local talent in the region.